Regeneron Pharmaceuticals(REGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low598.19
Day High616.24
Open:612.07
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Tipranks
Regeneron Advances First-in-Human Myeloma Combo Trial, Keeping Oncology Pipeline in Focus
Tipranks
Regeneron Shareholders Back Directors, Auditor and Executive Pay
Motley Fool
This Stock Is Up 58% This Year. Is It too Late to Buy?
StockStory
3 Profitable Stocks We Think Twice About
AMCX
Tipranks
Regeneron Tests Weekly Praluent Dosing in New Cholesterol Study: What Investors Should Watch
Tipranks
RAPID Real‑World Dupixent Data Could Extend Regeneron and Sanofi’s Asthma Edge
Zacks Investment Research
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
GlobeNewswire
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
StockStory
Why Regeneron (REGN) Stock Is Trading Up Today
REGN
Tipranks
Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors
Tipranks
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)
StockStory
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
REGN
Zacks Investment Research
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)
StockStory
3 Nasdaq 100 Stocks We Find Risky
INTC
Tipranks
Regeneron Advances Phase 3 ROXI-CAT-II Trial, Targeting Safer Cancer-Related Clot Treatment
Tipranks
Regeneron Targets Stroke Prevention Gap With New Atrial Fibrillation Trial
Tipranks
Regeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335
Tipranks
Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial

Profile

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.